Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

New Generation of Malaria Drugs Block Myristoylation in the Parasite

By BiotechDaily International staff writers
Posted on 02 Jan 2014
Image: Blood smear from a P. falciparum culture. Several red blood cells show ring stages inside them, while close to the center there is a schizont and on the left a trophozoite (Photo courtesy of Wikimedia Commons).
Image: Blood smear from a P. falciparum culture. Several red blood cells show ring stages inside them, while close to the center there is a schizont and on the left a trophozoite (Photo courtesy of Wikimedia Commons).
Researchers have identified the enzyme N-myristoyltransferase (NMT) as a target for a new generation of drugs to be used for the treatment of malaria.

Investigators from several research institutions in the United Kingdom taking part in a five-year project funded by the British Councils for Medical Research, Engineering and Physical Sciences Research, and Biotechnology and Biological Sciences Research recently described an integrated chemical biology approach that they had used to explore protein myristoylation in the major human malaria parasite Plasmodium falciparum.

N-myristoylation is a cellular process in which a myristoyl group (derived from myristic acid) is covalently attached via an amide bond to the alpha-amino group of an N-terminal amino acid of a nascent polypeptide. This modification ensures the proper function and intracellular trafficking of certain proteins. Many proteins involved in a wide variety of signaling, including cellular transformation and oncogenesis, are myristoylated.

The investigators reported in the December 22, 2013, online edition of the journal Nature Chemistry that NMT was an essential and chemically tractable target in malaria parasites both in vitro and in vivo, and that selective inhibition of N-myristoylation led to catastrophic and irreversible failure to assemble the inner membrane complex, a critical subcellular organelle in the parasite life cycle.

Senior author Dr. Edward W. Tate, professor of chemistry at Imperial College London (United Kingdom), said, "Finding an enzyme that can be targeted effectively in malaria can be a big challenge. Here, we have shown not only why NMT is essential for a wide range of important processes in the parasite, but also that we can design molecules that stop it from working during infection. It has so many functions that we think blocking it could be effective at preventing long-term disease and transmission, in addition to treating acute malaria. We expect it to work not just on Plasmodium falciparum, the most common malaria parasite, but the other species as well. We need to do some more work in the lab to find the best candidate molecule to take into clinical trials, but hopefully we will be ready to do that within a few years."

Related Links:

Imperial College London



WATERS CORPORATION

Channels

Genomics/Proteomics

view channel
Image: Electron micrograph of Hepatitis C virus purified from cell culture. Scale bar is 50 nanometers (Photo courtesy of the Center for the Study of Hepatitis C, the Rockefeller University).

Oxidized LDL Predicts Response to Interferon Treatment of Chronic Hepatitis C and May Be a Treatment Option

Oxidized low-density lipoprotein (oxLDL) in the blood was shown to predict responsiveness to interferon treatment in patients with chronic Hepatitis C virus (HCV) infection and to inhibit spread of the... Read more

Lab Technologies

view channel
Image: The gene assembly robot, the GeneTheatre (Photo courtesy of Analytik Jena AG).

Genomic Research Laboratories Await New Compact Liquid Handling System

A small footprint benchtop liquid handler that automates multiple gene assembly tasks and associated procedures such as PCR setup is now available for use by biotech and genomic research laboratories.... Read more

Business

view channel

NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology... Read more
 

Events

02 Jun 2015 - 03 Jun 2015
15 Jun 2015 - 18 Jun 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.